Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to $6.1 million.

  • aTYR PHARMA's Cash & Equivalents fell 4632.57% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year decrease of 4632.57%. This contributed to the annual value of $11.1 million for FY2024, which is 5096.26% down from last year.
  • Per aTYR PHARMA's latest filing, its Cash & Equivalents stood at $6.1 million for Q3 2025, which was down 4632.57% from $17.2 million recorded in Q2 2025.
  • Over the past 5 years, aTYR PHARMA's Cash & Equivalents peaked at $59.7 million during Q3 2021, and registered a low of $2.2 million during Q2 2021.
  • For the 5-year period, aTYR PHARMA's Cash & Equivalents averaged around $13.5 million, with its median value being $10.4 million (2025).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first crashed by 8986.69% in 2021, then skyrocketed by 32726.88% in 2022.
  • Over the past 5 years, aTYR PHARMA's Cash & Equivalents (Quarter) stood at $2.3 million in 2021, then skyrocketed by 327.27% to $10.0 million in 2022, then soared by 125.87% to $22.5 million in 2023, then plummeted by 50.96% to $11.1 million in 2024, then crashed by 44.37% to $6.1 million in 2025.
  • Its last three reported values are $6.1 million in Q3 2025, $17.2 million for Q2 2025, and $10.4 million during Q1 2025.